DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,738,611 | -30.1% | 1,150,684 | 0.0% | 1.21% | -34.1% |
| Q2 2023 | $33,956,685 | +45.2% | 1,150,684 | +13.4% | 1.84% | +98.5% |
| Q1 2023 | $23,378,319 | -17.2% | 1,014,684 | 0.0% | 0.92% | -25.9% |
| Q4 2022 | $28,218,362 | -9.4% | 1,014,684 | 0.0% | 1.25% | -35.0% |
| Q3 2022 | $31,141,000 | +4.3% | 1,014,684 | 0.0% | 1.92% | +12.6% |
| Q2 2022 | $29,862,000 | -8.5% | 1,014,684 | 0.0% | 1.71% | +14.6% |
| Q1 2022 | $32,642,000 | +118.4% | 1,014,684 | +202.7% | 1.49% | +95.3% |
| Q4 2021 | $14,949,000 | – | 335,184 | – | 0.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |